Clinical Effectiveness of Ertapenem Versus Piperacillin/Tazobactam in Patients With Mild to Moderate Intraabdominal Infections: A Systematic Review and Metaanalysis of Randomized Controlled Trials
{"title":"Clinical Effectiveness of Ertapenem Versus Piperacillin/Tazobactam in Patients With Mild to Moderate Intraabdominal Infections: A Systematic Review and Metaanalysis of Randomized Controlled Trials","authors":"M. Pezeshki, F. Soleymani, M. Seyedifar","doi":"10.34172/AJCMI.2020.28","DOIUrl":null,"url":null,"abstract":"Purpose: This study aimed to search for randomized clinical trials evaluating the clinical effectiveness of ertapenem compared to piperacillin/tazob actam in adult patients with mild to moderate intra-abdominal infections. Results: The analysis of 4 studies involving 767 patients in the ertapenem group and 728 patients in the piperacillin/tazobactam group showed that ertapenem can be 3% more effective than piperacillin/tazobactam (Weighted mean differences = 3.02, confidence interval (0.79-6.84) although the difference was insignificant (I-squared = 0.0%, P=0.98)","PeriodicalId":8689,"journal":{"name":"Avicenna Journal of Clinical Microbiology and Infection","volume":"15 1","pages":"129-134"},"PeriodicalIF":0.0000,"publicationDate":"2020-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Avicenna Journal of Clinical Microbiology and Infection","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34172/AJCMI.2020.28","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: This study aimed to search for randomized clinical trials evaluating the clinical effectiveness of ertapenem compared to piperacillin/tazob actam in adult patients with mild to moderate intra-abdominal infections. Results: The analysis of 4 studies involving 767 patients in the ertapenem group and 728 patients in the piperacillin/tazobactam group showed that ertapenem can be 3% more effective than piperacillin/tazobactam (Weighted mean differences = 3.02, confidence interval (0.79-6.84) although the difference was insignificant (I-squared = 0.0%, P=0.98)
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
